DNA Long Call Strategy
DNA (Ginkgo Bioworks Holdings, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NYSE.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
DNA (Ginkgo Bioworks Holdings, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $561.1M, a beta of 1.78 versus the broader market, a 52-week range of 5.37-17.58, average daily share volume of 1.2M, a public-listing history dating back to 2021, approximately 834 full-time employees. These structural characteristics shape how DNA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.78 indicates DNA has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a long call on DNA?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current DNA snapshot
As of May 15, 2026, spot at $7.70, ATM IV 98.10%, IV rank 21.67%, expected move 28.12%. The long call on DNA below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this long call structure on DNA specifically: DNA IV at 98.10% is on the cheap side of its 1-year range, which favors premium-buying structures like a DNA long call, with a market-implied 1-standard-deviation move of approximately 28.12% (roughly $2.17 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated DNA expiries trade a higher absolute premium for lower per-day decay. Position sizing on DNA should anchor to the underlying notional of $7.70 per share and to the trader's directional view on DNA stock.
DNA long call setup
The DNA long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With DNA near $7.70, the first option leg uses a $8.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed DNA chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 DNA shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $8.00 | $0.78 |
DNA long call risk and reward
- Net Premium / Debit
- -$77.50
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$77.50
- Breakeven(s)
- $8.78
- Risk / Reward Ratio
- Unbounded
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
DNA long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on DNA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -99.9% | -$77.50 |
| $1.71 | -77.8% | -$77.50 |
| $3.41 | -55.7% | -$77.50 |
| $5.11 | -33.6% | -$77.50 |
| $6.82 | -11.5% | -$77.50 |
| $8.52 | +10.6% | -$25.80 |
| $10.22 | +32.7% | +$144.34 |
| $11.92 | +54.8% | +$314.48 |
| $13.62 | +76.9% | +$484.63 |
| $15.32 | +99.0% | +$654.77 |
When traders use long call on DNA
Long calls on DNA express a bullish thesis with defined risk; traders use them ahead of DNA catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
DNA thesis for this long call
The market-implied 1-standard-deviation range for DNA extends from approximately $5.53 on the downside to $9.87 on the upside. A DNA long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current DNA IV rank near 21.67% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on DNA at 98.10%. As a Healthcare name, DNA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to DNA-specific events.
DNA long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. DNA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move DNA alongside the broader basket even when DNA-specific fundamentals are unchanged. Long-premium structures like a long call on DNA are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current DNA chain quotes before placing a trade.
Frequently asked questions
- What is a long call on DNA?
- A long call on DNA is the long call strategy applied to DNA (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With DNA stock trading near $7.70, the strikes shown on this page are snapped to the nearest listed DNA chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are DNA long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the DNA long call priced from the end-of-day chain at a 30-day expiry (ATM IV 98.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$77.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a DNA long call?
- The breakeven for the DNA long call priced on this page is roughly $8.78 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current DNA market-implied 1-standard-deviation expected move is approximately 28.12%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on DNA?
- Long calls on DNA express a bullish thesis with defined risk; traders use them ahead of DNA catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current DNA implied volatility affect this long call?
- DNA ATM IV is at 98.10% with IV rank near 21.67%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.